Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer

G. Füst, B. Fekete, I. Angyal, Ágnes Jakab, A. Pál, Katalin Merétey, A. Falus, Katalin Török, G. Szegedi, Mária Kávai, Èva Puskás, Mária Csécsi-Nagy, T. Szabó, Ágota Lenkey, Mária Misz

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In a collaborative study involving 7 laboratories, sera from 53 patients with lung cancer, 37 primary and 16 secondary tumours, and sera of 40 healthy blood donors were tested by 19 different assays or assay modifications used for detecting immune complexes. In 12 out of 19 assays, significantly higher immune complex levels were found in the cancer patients than in the healthy subjects. Assays based on interactions between immune complexes and Fc receptors of different cells (lymphocytes, macrophages or platelets) discriminated between cancer patients and healthy subjects and a high percentage (47-87%) of positivity was observed in such assays in patients with lung cancer. In contrast, none of the tests based on immune complex-complement interactions discriminated between cancer patients and healthy subjects. Immunochemical analyses of the PEG precipitates obtained from the sera tested revealed that the concentrations of IgG, IgA and C3 were significantly higher in the precipitates obtained from patients' sera than from control sera, but no significant differences were seen in IgM and C1q concentrations. A 100% correct classification of individuals tested was obtained on discriminant analysis of results with 3 assays: EA rosette inhibition, ADCC inhibition and C3 concentration in PEG precipitates. Correlation between results obtained with individual sera by the different assays was very poor: significant correlation coeffecients were found in only 13% of all possible paired comparisons. Our results suggest that Fc receptor-dependent assays are more suitable for detecting and measurement of circulating immune complexes in lung cancer than tests based on interactions with complement.

Original languageEnglish
Pages (from-to)259-276
Number of pages18
JournalJournal of Immunological Methods
Volume46
Issue number3
DOIs
Publication statusPublished - Nov 16 1981

Fingerprint

Antigen-Antibody Complex
Lung Neoplasms
Serum
Healthy Volunteers
Fc Receptors
Neoplasms
Antibody-Dependent Cell Cytotoxicity
Matched-Pair Analysis
Discriminant Analysis
Blood Donors
Immunoglobulin A
Immunoglobulin M
Blood Platelets
Immunoglobulin G
Macrophages
Lymphocytes

ASJC Scopus subject areas

  • Biotechnology
  • Immunology

Cite this

Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer. / Füst, G.; Fekete, B.; Angyal, I.; Jakab, Ágnes; Pál, A.; Merétey, Katalin; Falus, A.; Török, Katalin; Szegedi, G.; Kávai, Mária; Puskás, Èva; Csécsi-Nagy, Mária; Szabó, T.; Lenkey, Ágota; Misz, Mária.

In: Journal of Immunological Methods, Vol. 46, No. 3, 16.11.1981, p. 259-276.

Research output: Contribution to journalArticle

Füst, G, Fekete, B, Angyal, I, Jakab, Á, Pál, A, Merétey, K, Falus, A, Török, K, Szegedi, G, Kávai, M, Puskás, È, Csécsi-Nagy, M, Szabó, T, Lenkey, Á & Misz, M 1981, 'Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer', Journal of Immunological Methods, vol. 46, no. 3, pp. 259-276. https://doi.org/10.1016/0022-1759(81)90311-2
Füst, G. ; Fekete, B. ; Angyal, I. ; Jakab, Ágnes ; Pál, A. ; Merétey, Katalin ; Falus, A. ; Török, Katalin ; Szegedi, G. ; Kávai, Mária ; Puskás, Èva ; Csécsi-Nagy, Mária ; Szabó, T. ; Lenkey, Ágota ; Misz, Mária. / Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer. In: Journal of Immunological Methods. 1981 ; Vol. 46, No. 3. pp. 259-276.
@article{3af47046ebdd43e2acbbdc7b319d350e,
title = "Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer",
abstract = "In a collaborative study involving 7 laboratories, sera from 53 patients with lung cancer, 37 primary and 16 secondary tumours, and sera of 40 healthy blood donors were tested by 19 different assays or assay modifications used for detecting immune complexes. In 12 out of 19 assays, significantly higher immune complex levels were found in the cancer patients than in the healthy subjects. Assays based on interactions between immune complexes and Fc receptors of different cells (lymphocytes, macrophages or platelets) discriminated between cancer patients and healthy subjects and a high percentage (47-87{\%}) of positivity was observed in such assays in patients with lung cancer. In contrast, none of the tests based on immune complex-complement interactions discriminated between cancer patients and healthy subjects. Immunochemical analyses of the PEG precipitates obtained from the sera tested revealed that the concentrations of IgG, IgA and C3 were significantly higher in the precipitates obtained from patients' sera than from control sera, but no significant differences were seen in IgM and C1q concentrations. A 100{\%} correct classification of individuals tested was obtained on discriminant analysis of results with 3 assays: EA rosette inhibition, ADCC inhibition and C3 concentration in PEG precipitates. Correlation between results obtained with individual sera by the different assays was very poor: significant correlation coeffecients were found in only 13{\%} of all possible paired comparisons. Our results suggest that Fc receptor-dependent assays are more suitable for detecting and measurement of circulating immune complexes in lung cancer than tests based on interactions with complement.",
author = "G. F{\"u}st and B. Fekete and I. Angyal and {\'A}gnes Jakab and A. P{\'a}l and Katalin Mer{\'e}tey and A. Falus and Katalin T{\"o}r{\"o}k and G. Szegedi and M{\'a}ria K{\'a}vai and {\`E}va Pusk{\'a}s and M{\'a}ria Cs{\'e}csi-Nagy and T. Szab{\'o} and {\'A}gota Lenkey and M{\'a}ria Misz",
year = "1981",
month = "11",
day = "16",
doi = "10.1016/0022-1759(81)90311-2",
language = "English",
volume = "46",
pages = "259--276",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer

AU - Füst, G.

AU - Fekete, B.

AU - Angyal, I.

AU - Jakab, Ágnes

AU - Pál, A.

AU - Merétey, Katalin

AU - Falus, A.

AU - Török, Katalin

AU - Szegedi, G.

AU - Kávai, Mária

AU - Puskás, Èva

AU - Csécsi-Nagy, Mária

AU - Szabó, T.

AU - Lenkey, Ágota

AU - Misz, Mária

PY - 1981/11/16

Y1 - 1981/11/16

N2 - In a collaborative study involving 7 laboratories, sera from 53 patients with lung cancer, 37 primary and 16 secondary tumours, and sera of 40 healthy blood donors were tested by 19 different assays or assay modifications used for detecting immune complexes. In 12 out of 19 assays, significantly higher immune complex levels were found in the cancer patients than in the healthy subjects. Assays based on interactions between immune complexes and Fc receptors of different cells (lymphocytes, macrophages or platelets) discriminated between cancer patients and healthy subjects and a high percentage (47-87%) of positivity was observed in such assays in patients with lung cancer. In contrast, none of the tests based on immune complex-complement interactions discriminated between cancer patients and healthy subjects. Immunochemical analyses of the PEG precipitates obtained from the sera tested revealed that the concentrations of IgG, IgA and C3 were significantly higher in the precipitates obtained from patients' sera than from control sera, but no significant differences were seen in IgM and C1q concentrations. A 100% correct classification of individuals tested was obtained on discriminant analysis of results with 3 assays: EA rosette inhibition, ADCC inhibition and C3 concentration in PEG precipitates. Correlation between results obtained with individual sera by the different assays was very poor: significant correlation coeffecients were found in only 13% of all possible paired comparisons. Our results suggest that Fc receptor-dependent assays are more suitable for detecting and measurement of circulating immune complexes in lung cancer than tests based on interactions with complement.

AB - In a collaborative study involving 7 laboratories, sera from 53 patients with lung cancer, 37 primary and 16 secondary tumours, and sera of 40 healthy blood donors were tested by 19 different assays or assay modifications used for detecting immune complexes. In 12 out of 19 assays, significantly higher immune complex levels were found in the cancer patients than in the healthy subjects. Assays based on interactions between immune complexes and Fc receptors of different cells (lymphocytes, macrophages or platelets) discriminated between cancer patients and healthy subjects and a high percentage (47-87%) of positivity was observed in such assays in patients with lung cancer. In contrast, none of the tests based on immune complex-complement interactions discriminated between cancer patients and healthy subjects. Immunochemical analyses of the PEG precipitates obtained from the sera tested revealed that the concentrations of IgG, IgA and C3 were significantly higher in the precipitates obtained from patients' sera than from control sera, but no significant differences were seen in IgM and C1q concentrations. A 100% correct classification of individuals tested was obtained on discriminant analysis of results with 3 assays: EA rosette inhibition, ADCC inhibition and C3 concentration in PEG precipitates. Correlation between results obtained with individual sera by the different assays was very poor: significant correlation coeffecients were found in only 13% of all possible paired comparisons. Our results suggest that Fc receptor-dependent assays are more suitable for detecting and measurement of circulating immune complexes in lung cancer than tests based on interactions with complement.

UR - http://www.scopus.com/inward/record.url?scp=0019783982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019783982&partnerID=8YFLogxK

U2 - 10.1016/0022-1759(81)90311-2

DO - 10.1016/0022-1759(81)90311-2

M3 - Article

C2 - 6975788

AN - SCOPUS:0019783982

VL - 46

SP - 259

EP - 276

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 3

ER -